NCT01122875View on ClinicalTrials.gov

A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma

PHASE1CompletedINTERVENTIONAL

Enrollment

14

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions

Multiple Myeloma

Interventions

DRUG

MFGR1877S

Intravenous repeating dose

Trial Locations (12)

10065

New York

30322

Atlanta

48109

Ann Arbor

48201

Detroit

60611

Chicago

75246

Dallas

85259

Scottsdale

98109

Seattle

02111

Boston

07601

Hackensack

84132-0001

Salt Lake City

M5G 2M9

Toronto

Sponsors

Lead Sponsor

Genentech, Inc.

All Listed Sponsors

lead

Genentech, Inc.

INDUSTRY

NCT01122875 - A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma | Biotech Hunter | Biotech Hunter